12 November 2026

Tirzepatide boosts PsA control

4 minute read

Adding tirzepatide to ixekizumab more than doubled ACR50 response rates at 52 weeks, with additional benefits for weight loss and cardiometabolic health.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Register for a new account

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

Billing Address

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...

Specialist fees ‘out of control and getting worse’: Grattan

Knee OA care: funding the wrong fix

Oral IL-23 drug shows promise in PsA

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Log in

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover